• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by SciSparc Ltd.

    12/31/25 8:16:06 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRC alert in real time by email
    6-K 1 ea0269021-6k_scisparc.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    Under the Securities Exchange Act of 1934

     

    For the month of: December 2025 (Report No. 2)

     

    Commission file number: 001-38041

     

    SCISPARC LTD.

    (Translation of registrant’s name into English)

     

    20 Raul Wallenberg Street, Tower A

    Tel Aviv 6971916, Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒         Form 40-F ☐

     

     

     

     

     

    CONTENTS

     

    Change in Registrant’s Certifying Accountant 

     

    On December 9, 2025, the audit committee (the “Audit Committee”) of the board of directors (the “Board of Directors”) of SciSparc Ltd. (the “Company”) recommended the cessation of services by Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global (“EY”), as the Company’s independent registered public accounting firm and the appointment of Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, (“Deloitte”), as the Company’s new independent registered public accounting firm, subject to approval by the shareholders of the Company. The recommendation to appoint Deloitte followed a decision by the Company to consider alternatives in replacing EY as the Company’s independent registered public accounting firm. The decision to appoint Deloitte as the Company’s independent registered public accounting firm was approved by the Board of Directors.

     

    Under Israeli law, the Board of Directors’ approval of the appointment of Deloitte is subject to shareholder approval and therefore will be presented to the Company’s shareholders for a vote at the Company’s special general meeting.

     

    The audit report of EY on the Company’s consolidated financial statements as of and for the two years ended December 31, 2024, did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope, or accounting principles, except that EY's reports for the fiscal years ended December 31, 2024 and 2023, included an explanatory paragraph indicating that there was substantial doubt about the Company’s ability to continue as a going concern.

     

    In connection with the audits of the Company's financial statements for each of the two fiscal years ended December 31, 2024 and subsequent interim period through the date of the cessation of EY’s services, there were no disagreements with EY on any matters of accounting principles or practices, financial statement disclosure, or auditing scope and procedures which, if not resolved to the satisfaction of EY would have caused EY to make reference to the matter in their report on the Company’s financial statements.

     

    Neither the Company nor anyone acting on its behalf consulted with Deloitte with respect to (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the Company’s consolidated financial statements, and no written report or oral advice was provided to the Company that Deloitte concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii) any matter that was the subject of any disagreement of the type described in Item 16F of Form 20-F or a reportable event of the type described in Item 16F(a)(1)(v) of Form 20-F or a reportable event of the type described in Item 16F(a)(1)(v) of Form 20-F.

     

    The Company provided EY with a copy of the disclosures it is making in this Report of Foreign Private Issuer on Form 6-K and requested that EY furnish it with a letter addressed to the Securities and Exchange Commission (the “SEC”) stating whether or not EY agrees with the above disclosures and, if not, stating the respects in which EY does not agree. A copy of EY’s letter to the SEC, dated December 31, 2025, is furnished herewith as Exhibit 16.1 to this Report of Foreign Private Issuer on Form 6-K.

     

    1

     

     

    Special General Meeting

     

    Attached hereto and incorporated by reference herein is the Notice of Special General Meeting of Shareholders, Proxy Statement and Proxy Card for the Special General Meeting of Shareholders of the Company to be held on Wednesday, February 4, 2026 (the “Meeting”).

     

    Only shareholders of record who hold ordinary shares, no par value, of the Company at the close of business on Friday, January 9, 2026, will be entitled to notice of and to vote at the Meeting and any postponements or adjournments thereof.

     

    This Report of Foreign Private Issuer on Form 6-K and its exhibits, are incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-233417, 333-248670 and 333-255408) and on Form S-8 (File Nos. 333-278437, 333-225773 and 333-286791) filed with the SEC to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Exhibits No.     
    16.1   Letter from Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global addressed to the Securities and Exchange Commission, dated December 31, 2025.
         
    99.1  

    Notice and Proxy Statement for the Special General Meeting to be held on February 4, 2026.

         
    99.2  

    Proxy Card for the Special General Meeting to be held on February 4, 2026.

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      SciSparc Ltd.
       
    Date: December 31, 2025 By /s/ Oz Adler
      Name:  Oz Adler
      Title: Chief Executive Officer and Chief Financial Officer

     

    3

     

    Get the next $SPRC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SPRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

    SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing TEL AVIV, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the signing of a definitive agreement to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo"). The MUSE™ system is a single-use, innovative endoscopic device designed for transoral fu

    1/13/26 6:55:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

    TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it has received a written notification (the "Notification Letter") from the Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market, listing Rule 5550(b)(1), due to its failure to maintain a minimum of $2,500,000 in stockholders' equity. In the Company's Form 6-K dated No

    1/12/26 4:02:00 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

    TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the Israel Patent Office has granted a patent for its proprietary combination of opioids and N-acylethanolamines. This patent covers methods and formulations designed to potentiate the therapeutic effects of opioids while significantly reducing associated side effects, such as tolerance, dependence, and gastrointestin

    12/30/25 8:17:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    SEC Filings

    View All

    SEC Form 424B5 filed by SciSparc Ltd.

    424B5 - SciSparc Ltd. (0001611746) (Filer)

    1/14/26 8:29:05 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by SciSparc Ltd.

    6-K - SciSparc Ltd. (0001611746) (Filer)

    1/13/26 9:01:14 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by SciSparc Ltd.

    6-K - SciSparc Ltd. (0001611746) (Filer)

    1/13/26 7:10:31 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    Financials

    Live finance-specific insights

    View All

    SciSparc Adopts Limited Duration Shareholder Rights Plan

    TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag

    11/28/23 8:55:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel

    SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua

    11/22/23 7:42:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

    Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at

    9/27/23 7:58:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    Leadership Updates

    Live Leadership Updates

    View All

    SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

    As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a

    5/30/23 8:40:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

    JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U

    6/15/22 8:30:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

    Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed

    3/30/22 8:30:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SciSparc Ltd.

    SC 13G - SciSparc Ltd. (0001611746) (Subject)

    3/6/24 5:02:18 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SciSparc Ltd.

    SC 13G - SciSparc Ltd. (0001611746) (Filed by)

    12/13/22 6:22:30 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

    SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

    5/9/22 4:08:30 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care